Recon: FDA approves Teva’s generic obesity drug; Kennedy to testify on health agenda next week

• CDC Director Susan Monarez is ousted as her lawyers say ‘she will not resign’ (STAT)
• GOP Health chair Bill Cassidy vows Senate oversight after CDC shake-up (The Hill)
• Kennedy to testify before Senate panel on health agenda (Reuters)
• RFK Jr. defends CDC shakeup after high-level resignations (The Hill)
• CDC Vaccine Advisers Schedule September Meeting Amid Disarray (Bloomberg)
• FDA issues narrower approvals for Covid boosters, revokes emergency authorizations (STAT)
• Prasad explains why FDA revoked Pfizer's Covid vaccine EUA for children (Endpoints)
• US FDA approves Teva Pharmaceuticals' generic obesity drug (Reuters)
• US FDA declines to approve Outlook Therapeutics' drug for eye condition (Reuters)

• The most burdensome diseases globally are the least studied, but the gap is narrowing (STAT)
• NHS to lose out on new drugs, pharma firm warns (BBC)
• UK approves GSK's antibiotic for female urinary tract infections (Reuters)
• Drax Slumps on UK Probe Into Controversial Biomass Sourcing (Bloomberg)
• Stada CEO Says IPO Planned This Year in Boost to European Market (Bloomberg)
• Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge (Reuters)

• FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi (Reuters)
• Illumina CEO sees path to stable growth, even as its academic customers face funding uncertainty (STAT)
• An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines (STAT)
• Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss (Endpoints)
• Prothena really wants a partner for its Phase 1 Alzheimer's program that reported high ARIA-E events (Endpoints)
• REMS tweaks for Travere’s Filspari; AstraZeneca stops early-phase cardio study (Endpoints)
• Stanford spinout raises $21.5M to turn cancer drivers against themselves (Endpoints)
• Walgreens names new CEO and splits off Boots and other businesses as take-private deal closes (Endpoints)
• Novo Nordisk seeks new obesity, diabetes drugs with Replicate BioScience partnership (Reuters)
• Nvidia Forecast Is Looking Less Than Stellar (Bloomberg)
• Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex (Fierce Pharma)

• Novo Nordisk links to telehealth providers for patients seeking Wegovy (STAT)
• Epic’s ‘large medical model’ aims to change how hospitals predict patient risk (STAT)
• Engage the community in generative AI for public health (STAT)
• Why Twin Health is betting on 'digital twins' to tackle obesity (Endpoints)
• Intuitive to lay off 331 employees in California (MedTech Dive)
• Inspire CFO Rick Buchholz to step down at end of 2025 (MedTech Dive)
• No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’ (MedTech Insight)
• Qbeast Raises $7.6M To Tackle The Hidden Compute Tax In Open Data Lakehouses (MedTech Insight)
• Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation? (MedTech Insight)

• Baking association moves to eliminate FD&C colors in school food (Food Business News)
• FDA identifies new Salmonella outbreak; reopens investigation into another (Food Safety News)

• We surveyed hundreds of biomedical researchers about the instability in federal funding. Here’s what they said (STAT)
• New report details the state of the biotech industry in Mass. The results are grim (STAT)
• Health care giants are pushing hard for Congress to extend ACA insurance subsidies (STAT)
• Walgreens Replaces CEO and Splits Up After Sycamore Acquisition (Bloomberg)